Comparing the effect of high dose vitamin D3 intake on interleukin-10, 17 and quality of life in Multiple Sclerosis patients
Not Applicable
- Conditions
- Multiple sclerosis.
- Registration Number
- IRCT2015010910891N2
- Lead Sponsor
- Vice chancellor for research, Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
a definite diagnosis of Relapsing-remitting Multiple Sclerosis (RRMS) according to Mc Donald criteria? age 18 to 55 years? EDSS (Expanded Disability Status Scale) score of less than 4? no relapse 30 days before inclusion? negative ß-HCG test for women in child bearing age.
Exclusion criteria: pregnancy? lactation? any other disease than Multiple Sclerosis? receiving>4000IU/d vitamin D? past history of renal or hepatic disease? relapse during the study? received corticosteroids in the previous 30 days? Calcium (Ca)>11mg/dl? Aspartate Transaminase(AST) or Alanine Transaminase(ALT)>3 times normal values? alkaline phosphatase (ALP)>2.5 times normal values.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin 10, 17. Timepoint: At baseline and after 3 months. Method of measurement: Blood sample.
- Secondary Outcome Measures
Name Time Method Quality of life. Timepoint: 3 months. Method of measurement: MSQOL54.